JP2011522832A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522832A5
JP2011522832A5 JP2011512700A JP2011512700A JP2011522832A5 JP 2011522832 A5 JP2011522832 A5 JP 2011522832A5 JP 2011512700 A JP2011512700 A JP 2011512700A JP 2011512700 A JP2011512700 A JP 2011512700A JP 2011522832 A5 JP2011522832 A5 JP 2011522832A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
therapeutic agent
dose
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011512700A
Other languages
English (en)
Japanese (ja)
Other versions
JP5607613B2 (ja
JP2011522832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/046441 external-priority patent/WO2009149370A1/en
Publication of JP2011522832A publication Critical patent/JP2011522832A/ja
Publication of JP2011522832A5 publication Critical patent/JP2011522832A5/ja
Application granted granted Critical
Publication of JP5607613B2 publication Critical patent/JP5607613B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011512700A 2008-06-06 2009-06-05 関節リウマチの治療のための方法 Expired - Fee Related JP5607613B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5971108P 2008-06-06 2008-06-06
US61/059,711 2008-06-06
US9523208P 2008-09-08 2008-09-08
US61/095,232 2008-09-08
PCT/US2009/046441 WO2009149370A1 (en) 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014173653A Division JP5809338B2 (ja) 2008-06-06 2014-08-28 関節リウマチの治療のための方法

Publications (3)

Publication Number Publication Date
JP2011522832A JP2011522832A (ja) 2011-08-04
JP2011522832A5 true JP2011522832A5 (https=) 2014-04-10
JP5607613B2 JP5607613B2 (ja) 2014-10-15

Family

ID=40983388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011512700A Expired - Fee Related JP5607613B2 (ja) 2008-06-06 2009-06-05 関節リウマチの治療のための方法
JP2014173653A Expired - Fee Related JP5809338B2 (ja) 2008-06-06 2014-08-28 関節リウマチの治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014173653A Expired - Fee Related JP5809338B2 (ja) 2008-06-06 2014-08-28 関節リウマチの治療のための方法

Country Status (12)

Country Link
US (1) US20110189172A1 (https=)
EP (1) EP2293816B1 (https=)
JP (2) JP5607613B2 (https=)
AU (1) AU2009256072B2 (https=)
CA (1) CA2727171A1 (https=)
CY (1) CY1113640T1 (https=)
DK (1) DK2293816T3 (https=)
ES (1) ES2398693T3 (https=)
HR (1) HRP20130042T1 (https=)
PL (1) PL2293816T3 (https=)
PT (1) PT2293816E (https=)
WO (1) WO2009149370A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CA2772084C (en) 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
AU2011296356B2 (en) 2010-09-03 2015-07-09 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
WO2013139701A1 (en) * 2012-03-19 2013-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment or the prevention of aneurysm
CA2888583C (en) 2012-11-05 2022-03-29 Delenex Therapeutics Ag Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
CA2963606A1 (en) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
EP0364778B1 (en) * 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antibody against interleukin-1beta
EP0460052B1 (en) * 1989-02-27 1998-04-15 New England Medical Center Il-1 biological activity inhibitors
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) * 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) * 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US6727234B2 (en) * 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
EP1423432A4 (en) * 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
DK1899378T3 (da) * 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
TR201802449T4 (tr) * 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
CA2673592C (en) * 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
US8637029B2 (en) * 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout

Similar Documents

Publication Publication Date Title
JP2011522832A5 (https=)
JP2015007098A5 (https=)
JP2014503482A5 (https=)
Genovese et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
RU2018100129A (ru) Способы лечения подагры
JP2019088311A (ja) 抗ｉｌ−３３抗体及びその使用
JP2011507891A5 (https=)
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2017079785A5 (https=)
CN104800844A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
JP6469012B2 (ja) インターロイキン−６に対する抗体およびその使用
JP2016528247A5 (https=)
CN108310376A (zh) 用于治疗类风湿性关节炎的组合物及其使用方法
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
JP2012021001A5 (https=)
JP2016519650A5 (https=)
JP6255099B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2009511480A5 (https=)
JP2018535948A (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP2014114288A5 (https=)
JP2014169326A5 (https=)
RU2015114923A (ru) СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ
JP2013538796A5 (https=)
RU2014117510A (ru) Лечение ревматоидного артрита
JP2013526485A5 (https=)